

# PHESGO (COMBINATION OF PERTUZUMAB AND TRASTUZUMAB, HER2/NEU RECEPTOR ANTAGONISTS, AND HYALURONIDASE, AN ENDOGLYCOSIDASE) ORDER FORM

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_  
 Mobile Number: \_\_\_\_\_ Patient Weight: \_\_\_\_\_  
 Allergies: \_\_\_\_\_

## DIAGNOSIS (Provider must specify)

Use in combination with chemotherapy as:

- neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
- adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

Use in combination with:

- docetaxel for treatment of patients with HER2- positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease

Malignant neoplasm of the female breast, ICD 10: C50. \_\_\_\_\_

## PROVIDER INFORMATION

Provider Name (print name): \_\_\_\_\_ Provider NPI: \_\_\_\_\_  
 Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 Email Address: \_\_\_\_\_

**Prerequisites to treatment** – ensure the following information is complete and attached with referral:

- Demographics     Labs and tests supporting diagnosis     Office/progress notes

## PRE-MEDICATION

Acetaminophen (Tylenol) 500 mg PO     Famotidine 20 mg IV     Methylprednisolone (Solu-Medrol) 125 mg IVP  
 Benadryl 25mg PO     Cetirizine (Zyrtec) 10 mg PO  
 Other: \_\_\_\_\_ Dose: \_\_\_\_\_ Route: \_\_\_\_\_

## PHESGO (COMBINATION OF PERTUZUMAB AND TRASTUZUMAB, HER2/NEU RECEPTOR ANTAGONISTS, AND HYALURONIDASE, AN ENDOGLYCOSIDASE) ORDER FORM

### MEDICATION

MEDICATION	DOSE	ROUTE	FREQUENCY
Phesgo	<input type="checkbox"/> Initial dose: 1,200 mg pertuzumab 600 mg trastuzumab 30,000 units hyaluronidase followed by 600 mg pertuzumab 600 mg trastuzumab 20,000 units hyaluronidase	<input type="checkbox"/> Sub q	<input type="checkbox"/> Initial then every 3 weeks

New Start Therapy   
  Continuation of Therapy   
 Date of last dose (if applicable): \_\_\_\_\_

### LABS / SPECIAL INSTRUCTIONS